# Viking Therapeutics (VKTX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/VKTX
## Company Profile
- Ticker: VKTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cardio-Metabolic, Endocrinology
## Stock Data
- Close: 33.3 USD
- Market cap: 3400734283.47 USD
- Last updated: 2026-08-06
## Business Overview
### Obesity-Focused Metabolic Biotech
Viking Therapeutics is a clinical-stage biotechnology company advancing therapies for obesity and metabolic disease. Its pipeline is led by VK2735 and supported by additional obesity, liver/metabolic, and rare disease programs.
### Lead Franchise: VK2735
VK2735 is a wholly owned dual GLP-1/GIP receptor agonist in development for obesity and related metabolic disorders. Viking is developing both subcutaneous and oral formulations, giving the program a differentiated profile across induction, long-term maintenance, and patient preference.
### Phase 3 and Oral Development
The subcutaneous formulation is being evaluated in the Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials, both of which are fully enrolled. Viking is also preparing to start Phase 3 trials of oral VK2735 in the fourth quarter of 2026, positioning the oral program as a potential first oral dual GLP-1/GIP agonist.
### Broader Metabolic Pipeline
Viking is expanding the obesity franchise with VK3019, an investigational dual amylin and calcitonin receptor agonist now in Phase 1. The company also lists VK2809, an oral thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for X-linked adrenoleukodystrophy.
## Why The Stock Is Moving

As of Aug 6, 2026, VKTX closed down 0.63% at $33.30. No new same-company headline was identified in the current news window.

## Future Catalysts

- VK2735 maintenance dosing data expected in the third quarter of 2026.
- Phase 3 oral VK2735 trial initiation expected in the fourth quarter of 2026.
- VK3019 Phase 1 single-ascending-dose study readouts when the trial reports.

## Drug Assets

- VK2735

## Recent News
- 2026-07-29 20:05 EST — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce) — Source: Viking Therapeutics
- 2026-07-23 11:05 EST — [Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors](https://biopharmsignal.com/news/VKTX/viking-therapeutics-appoints-dorothy-gemmell-to-board-of-directors-d154bd33) — Source: Viking Therapeutics
- 2026-07-22 20:05 EST — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f) — Source: Viking Therapeutics
- 2026-06-24 11:05 EST — [Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-1-study-to-evaluate-novel-amyl-743d8a79) — Source: Viking Therapeutics
- 2026-06-11 11:05 EST — [Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-appointment-of-hubert-c-chen-m-d-as-chief-medical--ca51f016) — Source: Viking Therapeutics